Contribute Try STAT+ Today

In the latest look at clinical trial transparency, a new analysis found that only 26% of drug makers made results publicly available for all studies used to win approval for their medicines during a recent two-year period.

The total rose to 67% when examining trials that were conducted in patients for indications approved by the Food and Drug Administration. But just 58% of the trials met legal requirements for registering and disclosing results for drugs that were approved in 2016 and 2017. And 11% of the drugs did not have any trials for which results were legally required to be reported at the time of their approval.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment